The Current Ratio as of September 2024 (TTM) for Mersana Therapeutics, Inc. (MRSN) is 2.72

According to Mersana Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.72. This represents a change of -18.09% compared to the average of 3.32 of the last 4 quarters.

Mersana Therapeutics, Inc. (MRSN) Historical Current Ratio (quarterly & annually)

How has MRSN Current Ratio performed in the past?

The mean historical Current Ratio of Mersana Therapeutics, Inc. over the last ten years is 3.68. The current 2.72 Current Ratio has changed 7.28% with respect to the historical average. Over the past ten years (40 quarters), MRSN's Current Ratio was at its highest in in the June 2020 quarter at 13.15. The Current Ratio was at its lowest in in the March 2016 quarter at 0.

Mersana Therapeutics, Inc. (MRSN) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Mersana Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Mersana Therapeutics, Inc. (MRSN) Average Current Ratio

How has MRSN Current Ratio performed in the past?

The current Current Ratio of Mersana Therapeutics, Inc. (MRSN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Mersana Therapeutics, Inc. (MRSN) Current Ratio vs. Peers

How is MRSN’s Current Ratio compared to its peers?

Mersana Therapeutics, Inc.’s Current Ratio is less than Terns Pharmaceuticals, Inc. (21.02), less than Amylyx Pharmaceuticals, Inc. (4.66), less than Acumen Pharmaceuticals, Inc. (17.37), less than Inozyme Pharma, Inc. (9.84), less than X4 Pharmaceuticals, Inc. (6.07), less than Day One Biopharmaceuticals, Inc. (4.09), less than HOOKIPA Pharma Inc. (3.86), less than Theseus Pharmaceuticals, Inc. (29.93), less than Cullinan Oncology, Inc. (28.87), less than Relay Therapeutics, Inc. (15.64), less than Arcus Biosciences, Inc. (5.14), less than Kura Oncology, Inc. (14.94), less than Protagonist Therapeutics, Inc. (13.73), less than Merus N.V. (9.97), less than Replimune Group, Inc. (13.46), less than Cerevel Therapeutics Holdings, Inc. (10.22), less than Pliant Therapeutics, Inc. (14.47), less than Syndax Pharmaceuticals, Inc. (10.50), less than Revolution Medicines, Inc. (15.42), less than Viridian Therapeutics, Inc. (15.82),

Build a custom stock screener for Mersana Therapeutics, Inc. (MRSN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mersana Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Mersana Therapeutics, Inc. (MRSN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Mersana Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.